主页 > 医学新闻 >
【编译评论】默克或许隐瞒万络安全不利数据多
与国内药厂少有自动召回有安全和质量问题药品的低下社会责任感相比, 默克公司在全球范围召回万络的举措自然赢得媒体喝彩。但万络危机只是刚刚开始，继一个月前公司宣布召回后，股票下滑25%（股民损失200多亿美元市值）之后， 昨天又传来坏消息：公司以前可能是知道该药的危险隐患，只是刻意淡化或隐瞒这些信息。 据华尔街日报披露： 尽管2000 年3月9 日,从默克研究部的一位主任爱德华・Scolnick 博士对同事电子邮件可以看出：他承认万络引发心脏病发作和中风的风险有清楚的数据在那里，",但十分遗憾，默克继续设法给学术研究人员对该药的负面评价进行抹黑，以图该药能轻易的到FDA批准。
消息传来，默克股票又应声下滑近 10%， 华尔街近期都不看好默克，股票评级纷纷下调，预计默克将花费 120亿美元的天价来应对成千上万的病人法律诉讼官司。由于默克有隐瞒数据只嫌，官司必输无疑。另外默克有几个新药临床试验晚期失败，万络的二代产品将推迟一年上市，其他重磅药专利过期也严重影响默克产品的销售和利润。据了解，默克去年万络全球销售额达25亿美元，2000多万美国人用过该药，是默克销售总额11%的贡献者
默克股票在2000年底万络上市之后，曾高达 90多美元，昨天收盘 28.28美元, 有人甚至怀疑默克未来是否能继续独立存在, 但在其新产品上市之前，至少它将要熬一段痛苦的日子。
题外引伸：
中国每年有上百万人经历严重药品不良反应，20万人死于药品不良反应或不当用药，其中就没有质量和安全引起的问题吗？现行的法律和制度缺陷，药厂的社会责任感都需要反思和弥补。
Associated Press
Merck Shares Drop on Vioxx Denial Report
Monday November 1, 4:50 pm ET
Merck Shares Plunge More Than 10 Percent on Report It Hid Evidence of Vioxx Risks for Years
WHITEHOUSE STATION, N.J. (AP) -- Shares of Merck & Co. plunged more than 10 percent Monday after a media report said that documents show the pharmaceutical giant hid or denied evidence for years that its blockbuster arthritis drug Vioxx cause heart problems.
Merck, one of the world's top five drug makers, pulled the arthritis and acute pain drug from the market worldwide on Sept. 30, saying it was acting in patients' best interest. Vioxx has been taken by about 20 million Americans and had produced 11 percent of Merck's total revenues.
Also on Monday, Prudential Equity Group analyst Tim Anderson downgraded the stock's rating to neutral from overweight. Anderson wrote that he believes there is value in the company's drug pipeline but said it is likely to get lost in the negative Vioxx coverage.
Additionally, Standard & Poor's placed Merck on CreditWatch with negative implications, which sends a strong signal that the company's debt could be downgraded within the next three months. When Merck withdrew Vioxx, S&P lowered its outlook to negative from stable. The additional, more serious step taken Monday reflects the momentum in the Vioxx litigation and the delay in launching Arcoxia, Vioxx's successor drugs, said S&P analyst Arthur Wong.
Hundreds of lawsuits have been filed against Merck over Vioxx and one analyst believes it could cost the company up to $12 billion. Last Friday, the FDA said it wouldn't approve Arcoxia without additional safety and efficacy information. Wong said it look like the drug will be delayed more than a year.
Merck shares were down $3.03, or 9.7 percent, to close at $28.28 on the New York Stock Exchange after The Wall Street Journal reported that internal e-mails and marketing materials show the company knew as far back as 2000 that Vioxx was linked to an increased risk of heart attack but tried to discredit such evidence.
The news led to Merck posting the largest percentage decline Monday among stocks in the S&P 500 index.
Despite a March 9, 2000 e-mail from Merck research director Edward Scolnick to colleagues conceding an elevated risk of heart attack and stroke was "clearly there," according to the newspaper, Merck continued to try to discredit academic researchers critical of the drug.
The Journal reported that one training document from Merck listed potentially difficult questions about the drug and stated in capital letters, "DODGE!"
Merck declined comment on the article. Last Friday, Merck acknowledged some sealed trial documents had been made public, noting that in other similar court cases documents had been leaked to advance the plaintiffs' lawyers interests. It said that it "acted responsibly and appropriately as it developed and marketed Vioxx."
Merck shares had been trading in the $45 range until the withdrawal announcement, plunged to the mid $30s that day and have hovered just above $30 since then. The stock price was as high as $49 per share in February and was slightly above $90 at the end of 2000, before the recession. 药品的不良反应和副作用是显而易见的！我们作为医药领域的探索和传播者是不是应该担负起自己的职责？现在生活水平不断提高，人们对卫生健康事业和服务提出了更高的要求，所以无论从职业道德还是伦理道德来说，我们所从事的不仅是救治于人更是顾全人的生命安全！这就是我们的使命，一个有责任感的行业才能发展，一个有责任感的国家才能强盛！ 强烈支持－－－－－但是，是能不吃药就不吃药。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-17 09:11
医学,生命科学网